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Introduction
Vaccines represent the most 
important medical advance of 
the twentieth century. The time 
has passed when large numbers 
of children and adults suffered 
serious, life threatening illness 
from viruses including poliovirus, 
measles virus, influenza viruses, 
hepatitis B virus and varicella zoster 
virus or faced lifelong disability 
or death from bacterial infections 
including Hemophilus influenzae, 
meningococcus and pneumococcus, 
all infections that can be prevented 
now by effective vaccines. 
In this review, we discuss 
various aspects of vaccines for 
children and adults, including a 
description and recommendation 
of new vaccines, the importance of 
and improvements in established 
vaccines, and overcoming obstacles 
such as ethical dilemmas and office 
dynamics to improve uptake. We 
include two summary tables, Table 
1 and Table 2, which highlight 
vaccine immunization schedules for 
children and adults, respectively.1
Herpes zoster vaccine (Zostavax)
Key points: Zostavax is now 
approved for patients aged 50-59 
years. This age range has a better 
response with a 70% reduction 
in risk of getting shingles. It is 
not necessary to check varicella 
titers before giving the vaccine.
Approximately 1 in 3 people in 
the United States become ill with 
herpes zoster or shingles and 10-18% 
develop post-herpetic neuralgia, a 
devastating chronic pain syndrome. 
Zostavax became available in 2006.2 
It reduces the risk by one-half of 
shingles and by two-thirds the 
risk of post-herpetic neuralgia in 
immunized patients over age 60. 
Zostavax is not helpful in treating 
shingles or post-herpetic neuralgia. 
It can be administered to patients 
who previously had shingles as 
they experience a 3% recurrence 
rate. Persons with compromised 
immune systems and persons 
allergic to neomycin and gelatin 
should not take this vaccine.
Hepatitis A vaccine
Key points: Everyone over 
age 1 can get this vaccine.
Hepatitis A virus (HAV) causes 
foodborne illness that usually lasts 
2 months; however, 10-15% last up 
to 6 months. In rare cases, acute 
liver failure and death ensue. From 
1998 to 2008, 227 cases of HAV 
were reported in West Virginia.3 In 
2007, outbreaks of HAV occurred 
in Pendleton and Wirt Counties 
and, in 2010, an outbreak occurred 
among 11 people in Cabell County, 
WV, and nearby Boyd County, KY.
Although HAV is not required 
for children in schools or daycare 
centers, it is a good idea to vaccinate 
everyone over age 1 year. It is 
especially recommended for persons 
over age 18 that provide a home 
or day care for an international 
adopted child, men who have sex 
with men, illicit drug users, people 
with chronic liver disease from 
other causes, travelers to countries 
with high prevalence of HAV and 
researchers working with HAV.4
Hepatitis B vaccine
Key points: Anyone not in a 
monogamous sexual relationship 
should get this vaccine. Those born 
after 1991 have probably had it as part 
of routine childhood vaccination. 
 
What’s New: The ACIP now 
recommends Hepatitis B vaccine 
for diabetics especially those 
aged 19-59 with their increased 
risk being due to contaminated 
glucose monitoring equipment.
Hepatitis B virus (HBV) causes an 
acute illness with anorexia, diarrhea 
and vomiting and a chronic illness 
that can lead to cirrhosis, liver cancer, 
and death. Since 1991, newborns in 
the United States routinely receive 
their first dose of hepatitis B vaccine 
within 12 hours of birth, a program 
that decreased by over 95% the 
incidence of acute HBV illness among 
children.4 Because HBV is transmitted 
by blood and body fluids, anyone 
who is sexually active is at risk and 
Immunizations for Adults and Children
Objectives
1. Be able to describe recent changes in adult and pediatric vaccines.
2. Be able to apply knowledge about vaccines to clinical practice.
3. Be aware of recent outbreaks of certain vaccine preventable diseases in West Virginia.
4. Be able to improve office mechanics to improve vaccine uptake.
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persons at highest risk include sex 
partners and household contacts of 
those infected with HBV, men who 
have sex with men, intravenous 
drug abusers, healthcare workers, 
dialysis patients and travelers to 
countries with a high prevalence of 
HBV. Patients with HIV infection, 
chronic liver disease and diabetes 
should be vaccinated. A recombinant 
vaccine, hepatitis B vaccine 
involves insertion of the HBsAg 
gene using plasmids into yeast or 
mammalian cells; anyone with a 
life-threatening allergy to Baker’s 
yeast should not receive the vaccine.
Tetanus & Diphtheria Toxoids 
& Acellular Pertussis Vaccine 
(DTP/TT/Td/Dtap/Tdap)
What’s new: All healthcare personnel 
should receive a single dose of Tdap 
regardless of the time since last Td dose. 
Tdap should be administered during 
the second or third trimester to 
pregnant women or immediately 
postpartum. 
— Adults who have close contact with 
an infant less than 1 year old should 
have a Tdap. 
— All adolescents and adults 
can have one Tdap in place of 
their usual tetanus booster.
Although only 3 cases of tetanus 
have been reported in WV from 1999-
2008 and no cases of diphtheria, there 
have been 288 cases of pertussis or 
whooping cough (Figure 1).3 Adults 
either vaccinated against pertussis 
or having the disease in childhood 
show waning immunity, become 
susceptible to the disease and can 
transmit the disease to infants under 
1 year who have not yet developed 
full immunity. During 2001-2003, 
28,998 cases of pertussis were 
reported in the United States.5 In 
the older DPT vaccine, the pertussis 
component was derived from killed 
bacteria and it caused many serious 
adverse reactions in children. 
Recently, an acellular pertussis 
component was incorporated into 
the vaccine (DTaP for children less 
than 7 years old and Tdap for people 
over 11 years old) that elicits few 
adverse reactions. Td should be 
administered to adults every 10 years 
provided they previously received 
one Tdap as an adult. TT is given 
to adults who are allergic to the 
diphtheria portion of the vaccine.
Pneumococcal Vaccine PPV23 for 
Adults and PCV13 for Children
Key Points: The maximum number of 
doses of Pneumovax (PPV23) an adult 
should receive is two. 
What’s New: Asthma and smoking 
are now considered in the chronic 
medical condition category and adults 
with either of these risk factors get 
two doses, one before age 65 and one 
after age 65 years of age. 
PCV13, a conjugated vaccine, is the 
new standard of care vaccine for 
children. 
PCV13 is now FDA approved for 
people over age 50 but ACIP has 
not yet made recommendations.
Streptococcus pneumoniae causes 
serious disease among children 
and adults, with younger children 
and older adults most at risk.6 In 
WV from 1999 to 2008, 1,932 cases 
of invasive pneumococcal disease 
(IPD) were reported (Figure 1).3 
The current vaccine, comprised 
of 23 polysaccharides or PPV23, 
was licensed in 1983.7 Adults of 
average risk should receive only one 
dose of PPV23 after the age of 65 
years. Adults with chronic medical 
conditions including heart disease, 
chronic lung disease, diabetes 
mellitus, alcoholism, cerebrospinal 
fluid leaks and cochlear implants 
should receive one dose before age 
65 and one after age 65, provided at 
least 5 years have elapsed between 
the two doses. Immunocompromised 
adults should receive two doses 
five years apart; both doses can be 
given before the age of 65 years. 
Immunocompromised children who 
receive PPV23 before age 10 can 
receive a second dose three years 
later and those who receive their first 
dose after 10 years of age can receive 
a second dose five years later. Elderly 
patients should receive only one 
dose of PPV23 after 65 years of age, 
as the modest antibody responses to 
second doses do not warrant them. 
Protein-conjugated pneumococcal 
polysaccharide vaccine (PCV7) for 
infants and children was introduced 
in 2000 as one of the regularly 
scheduled immunizations for 
infants starting at age 2 months for 
the prevention of otitis media and 
invasive pneumococcal disease (IPD). 
The vaccine comprised of seven 
polysaccharides, each conjugated 
to minute amounts of diphtheria 
protein, induced higher antibody 
responses. It led to a significant 
decline in all IPD cases, especially 
in childhood IPD, due to the seven 
serotypes in PCV7, and a significant 
decline of IPD in adults due to the 
same serotypes, probably through 
decreased spread of these serotypes 
from grandchild to grandparent.8 
As five of the seven serotypes in 
PCV7 (6B,9V,14,19F,23) can develop 
penicillin resistance, the number 
of cases of penicillin resistant IPD 
also decreased. In 2010, PCV13 
supplanted PCV7 as the routinely 
used pneumococcal vaccine for 
infants and children. PCV13 contains 
13 pneumococcal serotypes and 
offers wider protection against IPD.7 
Influenza Vaccine
What’s New: Since 2010, all people 
over age 6 months should receive the 
influenza vaccine. New preparations 
include the high dose influenza vaccine 
for those over age 65, intradermal 
vaccine, and a quadrivalent live 
attenuated vaccine. The H1N1 strain 
is included in the 2011 vaccine.
The two seasonal influenza 
vaccines are a trivalent inactivated 
vaccine and a live attenuated 
influenza virus vaccine (LAIV) that 
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typically contain two type A strains 
and one type B strain; the included 
vaccine strains change annually.9 The 
inactivated virus vaccine comes in 
three CDC approved formulations: 
an intramuscular injection approved 
for ages 6 months and older, a high-
dose injection approved for ages 65 
years and older and an intradermal 
injection approved for ages 18-64 
years. The high-dose vaccine contains 
four-fold as much antigen as the 
traditional flu shot and produces 
a stronger immune response in 
older persons. The intradermal 
injection employs a needle that is 
90% smaller than the needle used 
for the intramuscular injection and 
contains 40% less antigen. LAIV, 
a nasal spray, is approved for 
healthy individuals 2-49 years of 
age. Immunocompromised persons 
should not receive LAIV. The first 
quadrivalent seasonal influenza 
vaccine was approved in February 
2012. It contains two Type A and 
two Type B strains. The quadrivalent 
vaccine is an LAIV which is also 
administered intranasally and is 
approved for the same patient 
population as the trivalent LAIV.
In 2010, the Advisory Committee 
on Immunization Practices 
recommended for the first time that 
all persons aged 6 months and older 
should receive influenza vaccine, 
unless contraindicated.9 Infants and 
children aged 6 months to 8 years 
who are receiving flu vaccine for the 
first time or who did not or may not 
have received a flu vaccine last year 
require two doses this season, at least 
28 days apart. Infants and children 
aged 6 months to 8 years who 
received only one dose of flu vaccine 
during the 2010-11 season would 
normally be recommended to receive 
two doses this season; however, 
since the formulation of the vaccine 
is the same for the 2011-12 season as 
for the 2010-11 season, a child in the 
6 months to 8 years age group who 
received at least one dose last year, 
only requires one dose this year. 
People who should not receive 
influenza vaccine include those with 
a severe egg allergy, a severe reaction 
to influenza vaccine, a history of 
Guillain-Barre syndrome associated 
with administration of influenza 
vaccine and infants younger than 
6 months of age. People with a 
moderate to severe illness with 
fever should delay immunization 
until they have recovered.
Poliovirus vaccine
Key point: There is only one 
poliovirus vaccine given at this time 
and it is the inactivated vaccine (IPV).
The immunization of infants, 
children and adults with poliovirus 
vaccine started in the late 1950’s, 
initially with the Salk inactivated 
poliovirus vaccine (IPV) and then the 
Sabin oral poliovirus vaccine (OPV), 
virtually eliminating poliomyelitis in 
the United States during the ensuing 
decades. However, after a few cases 
of paralytic polio occurred among 
adults who had received OPV, the 
CDC discontinued routine use of 
OPV in 2000 and now all infants, 
children and adults receive IPV.4
Measles, Mumps, and 
Rubella Vaccine (MMR)
Key Points: MMR is a live vaccine 
and should not be given to severely 
immunocompromised people.
MMR vaccine is a trivalent 
vaccine containing three live 
attenuated viruses for protection 
against measles, mumps and rubella 
infections. During the ten years from 
1999-2008 in WV, no cases of measles 
or rubella were detected and only 
34 cases of mumps were reported 
(Figure 1). In 2011, sixteen outbreaks 
of measles were reported in the 
United States, the largest occurred 
in Minneapolis and among the 21 
patients who contracted measles, 
16 patients were unvaccinated.10 
Varicella vaccine
What’s new: Since 2006, two doses 
are recommended, one at 12-15 
months and another at 4-6 years. It is 
now recommended for HIV positive 
children and adults with certain 
CD4 counts, namely lymphocyte 
percentages of 15-24% in children and 
CD4 counts greater than 200cells/
microliter in adolescents and adults.
Routine varicella vaccine usage has 
decreased hospitalizations and deaths 
from this disease. Deaths occur 
mainly among immunocompromised 
patients. After identifying a shift 
in the peak incidence in age of 
varicella cases among those who 
Figure 1.
Cumulative cases of selected vaccine preventable diseases in West Virginia, 1999-2008.
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received the vaccine once as an 
infant, the CDC recommendation 
changed to include a second dose 
of vaccine at age 4-6 years.4 
Human Papillomavirus 
vaccine (HPV2 and HPV4)
What’s new: HPV4 (quadrivalent) 
is now recommended for boys aged 
9-26 years to prevent genital warts.
Human papillomavirus 
vaccine (HPV, either bivalent or 
quadrivalent) is recommended for 
all girls starting at 11-12 years of age 
(range 9-26 years).11 The quadrivalent 
HPV vaccine prevents infection 
with four serotypes included in the 
vaccine, two of which cause most 
cervical cancers and genital warts. 
HPV4 is suggested for males 
9-26 years of age to prevent genital 
warts and possibly head and neck 
cancer. It reduces the risk of anal 
intraepithelial neoplasia in men who 
have sex with men. The recombinant 
vaccine is made in Baker’s yeast, 
so anyone with a severe yeast 
allergy should avoid the vaccine. 
Syncope has been reported after 
vaccination so each vaccinee should 
be observed for 15 minutes.
Meningococcal Vaccine (MCV4-
conjugate quadrivalent and MPSV4-
polysaccharide quadrivalent)
What’s new: Since 2010, the MCV4 
vaccine is given as a two dose series, 
the first at age 11-12 years and a 
booster at age 16 years. Persons with 
asplenia and complement deficiency 
should receive a booster every 5 years. 
MPSV4 is for people over age 56 years.
The meningococcal vaccine, which 
contains four of the most common 
meningococcal antigens, protects 
against about 80% of meningococcal 
disease. College students in their first 
and second years, especially those 
who live in campus dormitories, are 
at high risk of contracting the disease 
and many colleges now require proof 
of vaccination before attendance. The 
new requirements suggest a dose 
of vaccine within 5 years of starting 
college so those who received their 
first dose at age 11-12 should receive 
a booster after age 16 years.12 
Hemophilus influenza 
type B vaccine (Hib)
What’s new: Widespread use of Hib 
conjugate vaccine nearly completely 
eradicated invasive disease and 
eliminated nasopharyngeal carriage. 
Hib causes invasive disease 
and meningitis, with serious 
complications including mental 
retardation. Hib vaccine is available 
alone or in combination with 
other vaccines and need only 
be administered at 2 , 4, and 6 
months of age.4 A booster dose is 
administered at 12-15 months.
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Rotavirus
What’s new: There are now two 
approved vaccines, RV5 and RV1, 
both live oral vaccines and about 
74-87% effective at preventing 
the disease. Intussusception is 
not increased in recipients.
Before vaccine, four of five 
children experienced rotavirus 
infection by age 5 and this 
illness accounted for 30-50% of 
hospitalizations among this age 
group.4 RV5, a live oral vaccine, 
shows 98% effectiveness in 
preventing severe disease. RV1 
appears to have similar rates 
of efficacy. RV1 has latex in the 
applicator and should not be 
administered to persons with 
latex allergy. RV5 is latex-free. 
Ethical issues about vaccines
Parents who deny vaccines for 
their children, except for specific 
medical conditions confirmed by 
a physician, fail to act in the best 
interests of their children, religious 
beliefs notwithstanding. Physicians 
have an ethical responsibility to 
address their reasons for refusal and 
explain the risk and benefit. School 
districts in every state require routine 
immunizations of children before 
they start kindergarten, an important 
ethical prevention program.
Some parents who refuse vaccines 
for their children, especially MMR, 
may worry that the vaccines 
cause autism. Unfortunately, that 
relationship was fostered by one 
group of researchers from the UK 
who published falsified data for 
personal gain.13 Subsequently, several 
studies provided evidence that 
refuted autism as an adverse event of 
immunization with MMR vaccine.14
Table 1. Recommendations for Routine Immunization of Children 0-8 Years of Age
Vaccine Code
Number
of
Doses
First
Dose at 
Age
Additional
Doses at Ages Notes
VIRUS VACCINES
Hepatitis B HepB 3 Birth 1-2m, 6-18m Give HBIG within 12h of birth if Mother HbsAg positive
Hepatitis A HepA 2 12-23 m 12-23m Two doses at least 6m apart
Influenza, seasonal Flu
2 6m-8y At least 4w after 
first dose
First year receiving vaccine
1 Over 8y Annually Administer one dose each Fall
Measles, mumps, rubella MMR 2 12-15m 4-6y
Can give second dose before 4y 
if at least 4 weeks between two 
doses
Poliovirus, inactivated IPV 4 2 m 4m, 6-18m, 4-6y Final dose on or after 4y of age
Rotavirus RV 3 2 m 4m, 6m No dose at 6m if Rotarix given at 2 and 4m
Varicella Var 2 12-15m 4-6y Age 12m-12y need at least 3m between doses
BACTERIAL VACCINES
Diphtheria, tetanus, pertussis DTap 5 2m 4m, 6m, 12-18m, 4-6y
Need at least 6m between 2nd
and 3rd doses
Haemophilus influenza type b Hib 4 2m 4m, 6m, 12-15m No dose at 6m if PedVaxHIB or Comvax given at 2 and 4m
Meningococcal MCV4 1 2-6y 2-6y High risk only
Pneumococcal PCV13 4 2m 4m, 6m, 12-15m Complete PCV7 series with PCV13
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Table 2. Recommendations for Routine Immunization of Adults
Vaccine Code Numberof Doses Age Range for Immunization Notes
VIRUS VACCINES
Hepatitis B HepB 3
All adults at high risk 19 years 
and older, especially health 
care persons
Administer 2nd dose 1 month 
later; 3rd dose at least 2 
months after 2nd
Hepatitis A HepA 2
All adults at high risk19 years 
and older including travelers to 
countries with high endemicity
Two doses at least 6m apart
Influenza, seasonal Flu 1 All adults 19 years and older Annual immunization
Measles, mumps, rubella MMR
1or 2 19-49 years if unvaccinated Persons who lack immunity
1 50 years and older if unvaccinated Persons who lack immunity
Human papillomavirus HPV 3 Women 13-26 years, Men 9-26 years HPV4
Administer 2nd dose 1-2 
months later and 3rd dose 6 
months after 2nd dose
Zoster HZ 1 50 years and older Administer to persons who have or have not had shingles
Varicella VZV 2
19 years and older if 
unvaccinated or otherwise lack 
immunity
Persons who lack immunity
BACTERIAL VACCINES
Diphtheria, tetanus, pertussis Td,Tdap
1 19 to 64 years 1-time dose of Tdap, Td vaccine every 10 y
1 65 years and older 1-time dose of TdapTd vaccine every 10 y
Meningococcal
MCV4 1 or 2 55 years and younger
1 or 2 doses for pre-college 
students and booster every 5 
years for high risk adults
MPSV4 1 56 years and older Single dose
Pneumococcal PPV23 1 or 2
1 dose before age 65 years for 
high risk adults; 1 dose for all 
adults over 65 years
Second dose should be at 
least 5 years after first dose 
and after age 65 years
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Recently, the US Court of Federal 
Claims ruled that the “theory of 
vaccine-related causation [of autism] 
is scientifically unsupportable,” 
that thimerosal-containing 
vaccines do not cause autism.
How can we increase vaccine 
uptake?
Physicians should initiate office 
procedures that are proven to 
increase immunization rates. First, 
employ standing orders for influenza 
and pneumococcal vaccines for 
adults. We reported a retrospective 
study of standing orders for elderly 
patients that showed higher rates of 
immunizations than when individual 
orders were relied on at each 
visit.15 Second, communicate using 
reminders for un-immunized at-risk 
patients. Third, since Medicare data 
for the US and West Virginia show 
that only about two-thirds of elderly 
adults have been immunized with 
PPV23 we should take advantage 
of opportunities to promote this 
vaccine such as in the annual 
Medicare wellness visit and when 
patients present for their influenza 
vaccine. Even though PPV23 can 
be administered any time of the 
year, data collected in our practice 
showed that influenza vaccine season 
provided the trigger to remind 
physicians to offer PPV23.16 Finally, 
physicians should be advocates for 
vaccines and provide education 
about their need as uncertainty about 
the need for H1N1 vaccine among 
elderly in 2009 prevented many of 
them from getting the vaccine.17 
The admonition that “an ounce 
of prevention is worth a pound of 
cure” applies to vaccines more than 
any other medical advance. During 
the past six decades established 
and new vaccines pushed many 
viral and bacterial diseases into the 
background by preventing a myriad 
of serious illnesses and saving untold 
numbers of lives. The systematic, 
appropriate and conscientious 
use of vaccines among children 
and adults in West Virginia will 
promote their health and reduce 
serious disease among them. 
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CME Post-test
4.  A 65 year old man with a history of hypertension 
only should receive the pneumococcal vaccine
a. every 5 years
b. 2 doses, 5 years apart
c. once
d. as PCV7 which is indicated for adults
5. Which is true about influenza vaccine?
a.  It comes in a new high dose formulation 
for people over age 65 years
b. Live attenuated vaccine is given by injection
c. Live attenuated vaccine is for people over age 50
d.  People with fever and moderate illness 
should still get the vaccine that visit
6.  A 70 year old female has a new grandchild and 
asks about Tdap vaccine. Which is true?
a.  She doesn’t need it if she had 
whooping cough as a child
b.  She needs to wait until 10 years 
after her last tetanus shot
c.  She should not get it because it is 
not indicated over age 65 
d. She should get it as soon as possible
